Literature DB >> 26113534

Syk and tired of current chronic GVHD therapies.

Daniel H Fowler1, Steven Z Pavletic1.   

Abstract

In this issue of Blood, Flynn et al1 provide key data that lend further support to the development of clinical trials of spleen tyrosine kinase (Syk) inhibition for more effective chronic graft-versus-host disease (cGVHD) treatment.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26113534      PMCID： PMC4481589          DOI： 10.1182/blood-2015-05-640672

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  10 in total

1.  Spleen tyrosine kinase (Syk) is a potent target for GvHD prevention at different cellular levels.

Authors:  F Leonhardt; K Zirlik; M Buchner; G Prinz; A-K Hechinger; U V Gerlach; P Fisch; A Schmitt-Gräff; W Reichardt; R Zeiser
Journal:  Leukemia       Date:  2012-01-17       Impact factor: 11.528

Review 2.  Small-molecule inhibitors of spleen tyrosine kinase as therapeutic agents for immune disorders: will promise meet expectations?

Authors:  Matthew C Lucas; Seng-Lai Tan
Journal:  Future Med Chem       Date:  2014       Impact factor: 3.808

3.  2014 National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: preface to the series.

Authors:  Steven Z Pavletic; Georgia B Vogelsang; Stephanie J Lee
Journal:  Biol Blood Marrow Transplant       Date:  2015-01-05       Impact factor: 5.742

4.  Ibrutinib treatment ameliorates murine chronic graft-versus-host disease.

Authors:  Jason A Dubovsky; Ryan Flynn; Jing Du; Bonnie K Harrington; Yiming Zhong; Benjamin Kaffenberger; Carrie Yang; William H Towns; Amy Lehman; Amy J Johnson; Natarajan Muthusamy; Steven M Devine; Samantha Jaglowski; Jonathan S Serody; William J Murphy; David H Munn; Leo Luznik; Geoffrey R Hill; Henry K Wong; Kelli K P MacDonald; Ivan Maillard; John Koreth; Laurence Elias; Corey Cutler; Robert J Soiffer; Joseph H Antin; Jerome Ritz; Angela Panoskaltsis-Mortari; John C Byrd; Bruce R Blazar
Journal:  J Clin Invest       Date:  2014-10-01       Impact factor: 14.808

5.  Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease.

Authors:  Ryan Flynn; Jessica L Allen; Leo Luznik; Kelli P MacDonald; Katelyn Paz; Kylie A Alexander; Ante Vulic; Jing Du; Angela Panoskaltsis-Mortari; Patricia A Taylor; Jonathan C Poe; Jonathan S Serody; William J Murphy; Geoffrey R Hill; Ivan Maillard; John Koreth; Corey S Cutler; Robert J Soiffer; Joseph H Antin; Jerome Ritz; Nelson J Chao; Raphael A Clynes; Stefanie Sarantopoulos; Bruce R Blazar
Journal:  Blood       Date:  2015-04-07       Impact factor: 22.113

6.  Blockade of Syk ameliorates the development of murine sclerodermatous chronic graft-versus-host disease.

Authors:  Doanh Le Huu; Hiroshi Kimura; Mutsumi Date; Yasuhito Hamaguchi; Minoru Hasegawa; Khang Tran Hau; Manabu Fujimoto; Kazuhiko Takehara; Takashi Matsushita
Journal:  J Dermatol Sci       Date:  2014-03-12       Impact factor: 4.563

Review 7.  Calling in SYK: SYK's dual role as a tumor promoter and tumor suppressor in cancer.

Authors:  Mariya O Krisenko; Robert L Geahlen
Journal:  Biochim Biophys Acta       Date:  2014-11-04

8.  Rituximab for steroid-refractory chronic graft-versus-host disease.

Authors:  Corey Cutler; David Miklos; Haesook T Kim; Nathaniel Treister; Sook-Bin Woo; Don Bienfang; Lloyd B Klickstein; Jesse Levin; Katherine Miller; Carol Reynolds; Rebecca Macdonell; Mildred Pasek; Stephanie J Lee; Vincent Ho; Robert Soiffer; Joseph H Antin; Jerome Ritz; Edwin Alyea
Journal:  Blood       Date:  2006-03-21       Impact factor: 22.113

9.  Syk tyrosine kinase is critical for B cell antibody responses and memory B cell survival.

Authors:  Jochen A Ackermann; Josquin Nys; Edina Schweighoffer; Scott McCleary; Nicholas Smithers; Victor L J Tybulewicz
Journal:  J Immunol       Date:  2015-04-10       Impact factor: 5.422

10.  Simultaneous assessment of rotavirus-specific memory B cells and serological memory after B cell depletion therapy with rituximab.

Authors:  Daniel Herrera; Olga L Rojas; Carolina Duarte-Rey; Rubén D Mantilla; Juana Angel; Manuel A Franco
Journal:  PLoS One       Date:  2014-05-12       Impact factor: 3.240
  10 in total
  3 in total

Review 1.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report.

Authors:  Kirsten M Williams; Yoshihiro Inamoto; Annie Im; Betty Hamilton; John Koreth; Mukta Arora; Iskra Pusic; Jacqueline W Mays; Paul A Carpenter; Leo Luznik; Pavan Reddy; Jerome Ritz; Hildegard Greinix; Sophie Paczesny; Bruce R Blazar; Joseph Pidala; Corey Cutler; Daniel Wolff; Kirk R Schultz; Steven Z Pavletic; Stephanie J Lee; Paul J Martin; Gerard Socie; Stefanie Sarantopoulos
Journal:  Transplant Cell Ther       Date:  2021-03-02

Review 2.  New Approaches for the Treatment of Chronic Graft-Versus-Host Disease: Current Status and Future Directions.

Authors:  Nathaniel Edward Bennett Saidu; Chiara Bonini; Anne Dickinson; Magdalena Grce; Marit Inngjerdingen; Ulrike Koehl; Antoine Toubert; Robert Zeiser; Sara Galimberti
Journal:  Front Immunol       Date:  2020-10-09       Impact factor: 7.561

Review 3.  Kinase Inhibition as Treatment for Acute and Chronic Graft-Versus-Host Disease.

Authors:  Lukas M Braun; Robert Zeiser
Journal:  Front Immunol       Date:  2021-11-17       Impact factor: 7.561
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.